SCHEMBL4310883

SCHEMBL4310883

O=CC1CCCN1S(=O)(=O)c1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.52
FKBP1A P62942 2/20 0.48
TSHR P16473 2/20 0.48
ALDH1A1 P00352 2/20 0.48
L3MBTL1 Q9Y468 1/20 0.47
CYP3A4 P08684 2/20 0.47
CYP2C19 P33261 2/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2C9 P11712 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
MMP2 P08253 1/20 0.47
MMP9 P14780 1/20 0.47
RAB9A P51151 1/20 0.46
KMT2A Q03164 1/20 0.46
PSEN1 P49768 1/20 0.46
PSEN2 P49810 1/20 0.46
APH1B Q8WW43 1/20 0.46
NCSTN Q92542 1/20 0.46
APH1A Q96BI3 1/20 0.46
PSENEN Q9NZ42 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7188833 1.00 LMNA (0.52) LMNAFKBP1ATSHRALDH1A1L3MBTL1
SCHEMBL3920618 0.86 LMNA (0.51) LMNAFKBP1ATSHRALDH1A1L3MBTL1
SCHEMBL9042461 0.84 L3MBTL1 (0.51) FKBP1ATSHRALDH1A1L3MBTL1KMT2A
SCHEMBL6879707 0.84 L3MBTL1 (0.51) FKBP1ATSHRALDH1A1L3MBTL1KMT2A
SCHEMBL10904190 0.84 L3MBTL1 (0.51) FKBP1ATSHRALDH1A1L3MBTL1KMT2A
SCHEMBL10870111 0.83 MCOLN3 (0.54) LMNATSHRALDH1A1SMN1; SMN2KMT2A
SCHEMBL8268313 0.79 HTR2A (0.46) FKBP1ATSHRALDH1A1SMN1; SMN2KMT2A
SCHEMBL7450743 0.78 ITGB1 (0.48) SMN1; SMN2PSEN1PSEN2APH1BNCSTN
SCHEMBL16431386 0.77 TSHR (0.44) LMNATSHRALDH1A1L3MBTL1CYP3A4
SCHEMBL16220206 0.77 ACHE (0.50) LMNAFKBP1AALDH1A1SMN1; SMN2MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021113922-A1 IMPROVED METHOD FOR PREPARING N-(BENZENESULFONYL)-L-PROLYL- L-O-(1-PYRROLIDINYLCARBONYL)TYROSINE COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 2021-06-17 WO disclosed
US-8084448-B2 Organic compounds NOVARTIS AG (CH) 2011-12-27 US disclosed
US-20090181928-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-07-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181928-A1 ORGANIC COMPOUNDS PTPRS, PTPRO, PTPRC LMNA 4825/4885FKBP1A 766/4885TSHR 2200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.